Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category by Luger, Dror et al.
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           IL-23 is a recently described member of the 
IL-12 family. Both cytokines share a common 
p40 subunit, but IL-23 has a unique p19 sub-
unit whereas IL-12 uses a p35 subunit (  1  ). IL-12 
and IL-23 promote overlapping as well as 
distinct cellular immune functions. Whereas 
IL  –  12 is well known for promoting the IFN-
      –  producing Th1 eff  ector phenotype in the 
adaptive response, IL-23 is reported to promote 
IL-17  –  producing eff  ector T cells that consti-
tute a separate lineage from Th1 and Th2 and 
have been appropriately dubbed   “  Th17.  ”   Recent 
studies have suggested that these cells may have 
an important role in cell-mediated autoimmune 
infl  ammatory diseases. 
  Experimental autoimmune uveitis (EAU) 
serves as a model for several human ocular dis-
eases of suspected autoimmune etiology (  2  –  4  ). 
EAU is elicited by immunization with retinal 
antigens (Ags) or their fragments (  5  ), or by adop-
tive transfer of retinal Ag-specifi  c CD4  +   T cells 
between syngeneic rodents (  6, 7  ). Published 
data provide evidence that a Th1-dominant re-
sponse and the Th1 eff  ector cell are critical for 
EAU development and that endogenous IL-12 
is needed for EAU induction and its full ex-
pression (  8, 9  ). However, susceptibility to EAU 
of IFN-      –  defi  cient (GKO) mice, exacerbation 
of EAU by neutralization of endogenous IFN-    , 
and the protective eff  ects of high systemic IFN-     
in WT mice (  10  –  12  ) were in apparent paradox 
with this notion. 
  The requirement for IL-12  –  mediated IFN-     
and Th1 responses in autoimmune infl  amma-
tion has recently been questioned by several 
studies in other disease models. Mice defi  cient 
in IFN-    , IFN-    R, IL-12R    2, and the IL-
12p35 chain were highly susceptible to experi-
mental autoimmune encephalomyelitis (EAE) 
and collagen-induced arthritis (CIA) (  13  –  15  ). In 
contrast, IL-23 and the IL-17  –  producing eff  ec-
tor T cell whose diff  erentiation and maintenance 
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in the pathogenesis of EAU. IL  –  23 but not IL-12 was necessary to elicit disease by immuni-
zation with the retinal antigen (Ag) interphotoreceptor retinoid-binding protein (IRBP) in 
complete Freund  ’  s adjuvant. IL-17 played a dominant role in this model; its neutralization 
prevented or reversed disease, and Th17 effector cells induced EAU in the absence of 
interferon (IFN)-    . In a transfer model, however, a polarized Th1 line could induce severe 
EAU independently of host IL-17. Furthermore, induction of EAU with IRBP-pulsed mature 
dendritic cells required generation of an IFN-      –  producing effector response, and an IL-17 
response by itself was insuffi  cient to elicit pathology. Finally, genetic defi  ciency of IL-17 
did not abrogate EAU susceptibility. Thus, autoimmune pathology can develop in the con-
text of either a Th17 or a Th1 effector response depending on the model. The data suggest 
that the dominant effector phenotype may be determined at least in part by conditions 
present during initial exposure to Ag, including the quality/quantity of Toll-like receptor 
stimulation and/or type of Ag-presenting cells. These data also raise the possibility that the 
nonredundant requirement for IL-23 in EAU may extend beyond its role in promoting the 
Th17 effector response and help provide a balance in the current Th1 versus Th17 paradigm. 800 ROLE OF IL-23 AND IL-17 IN EAU | Luger et al.
that the DTH response to IRBP was well correlated with EAU 
scores of the respective mice, showing signifi  cantly lower re-
sponse for the p19 and p40 KO mice and signifi  cantly higher 
response for the p35 KO compared with the WT (  Fig. 1 B  ). In 
keeping with their EAU and DTH responses, the p19 KO and 
p40 KO mice also revealed reduced amounts of all measured 
proinfl  ammatory cytokines compared with the WT, without 
an obvious skewing toward a Th2 cytokine profi  le (  Fig. 1 D  ). 
In contrast, p35 KO mice revealed elevated levels of IL-17 and 
TNF-     compared with WT (  Fig. 1 D  ). 
  Inductive role of IL-23: systemic neutralization of IL-23 
prevents, but does not reverse, EAU 
  The requirement for IL-23 to develop EAU suggests that 
this cytokine could serve as a therapeutic target. The most 
are promoted by IL-23 were found to be necessary for induc-
tion of these diseases (  15, 16  ). The activity of the IL-17  –
  producing eff  ector T cells (Th17) was associated with induction 
of proinfl  ammatory cytokines such as TNF-    , IL-1, IL-6, 
and IL-8, as well as with enhanced proliferation, maturation, 
and chemotaxis of neutrophils. These results led to the notion 
that the pathogenic eff  ects previously attributed to the IL-12  –
  IFN-     pathway are in fact largely if not solely mediated by 
IL-23 and the IL-23  –  driven Th17 eff  ector (  15, 17  ). 
  The present study was conducted to examine the role of 
the IL-23  –  IL-17 pathway in interphotoreceptor retinoid-
binding protein (IRBP)-induced EAU. Our data indicate 
that IL-23, rather than IL-12, is necessary for EAU induction 
and exerts its role early in the response. We demonstrate that 
IL-17 plays a role in the pathogenesis of EAU induced by 
immunization in CFA, and that targeting IL-17 even late in 
the disease process can ameliorate pathology, indicating an 
eff  ector role for this cytokine in pathogenesis of this type of 
EAU. Notably, however, severe EAU could be induced by 
uveitogenic Th1 cells without participation of host IL-17, 
and pathology of EAU induced with uveitogenic Ag-pulsed 
DCs required induction of an IFN-      –  producing eff  ector T 
cell response. Finally, genetically IL-17  –  defi  cient mice were 
able to develop substantial disease. Thus, in some situations 
Ag-specifi  c IL-17  –  producing eff  ector T cells appear to be 
dispensable for pathogenesis. The data put in perspective the 
role of Th17 versus other eff  ector mechanisms in autoimmune 
infl  ammation and suggest that the essential role of IL-23 in 
ocular autoimmunity may transcend its ability to drive the 
Ag-specifi  c IL-17 eff  ector response. 
    RESULTS   
  IL-23 is essential for induction of EAU and proinfl  ammatory 
cytokine responses 
  Earlier studies that indicated a necessary role for IL-12 in EAU 
were based on p40 KO mice and neutralizing anti-p40 anti-
bodies, and did not diff  erentiate between the roles of IL-12 
and IL-23. To investigate the eff  ect of IL-23 on EAU devel-
opment, we immunized WT, p40 KO, p35 KO, and p19 KO 
strains with a uveitogenic protocol of IRBP in CFA. Determi-
nation of EAU score 21 d after immunization revealed a sig-
nifi  cant reduction in the p19 and p40 KO mice compared 
with the WT, whereas EAU scores were signifi  cantly increased 
in the p35 KO mice (  Fig. 1 A  ).   Evaluation of EAU pathology 
revealed severe retinal damage in the p35 KO mice, whereas 
the p19 and p40 KO mice maintained healthy retinas (  Fig. 1 C  ). 
Interestingly, the composition of the infl  ammatory infi  ltrate in 
the eyes of the p35 KO diff  ered from the WT, with the for-
mer dominated by macrophages and the latter by lymphocytes 
(not depicted), which may be related to diff  erences in the cyto-
kine response profi  le of these strains (see below). 
  We next examined the adaptive immune responses 21 d af-
ter immunization. Mice challenged with IRBP in their ear pin-
nae 48 h earlier were assessed for delayed-type hypersensitivity 
(DTH) responses, and their lymphoid cells were collected for 
analysis of Ag-specifi  c cytokine production. The results showed 
    Figure 1.         IL-23 is essential for EAU induction by up-regulating 
proinfl  ammatory cytokine.   (A) EAU scores were evaluated by histopa-
thology of eyes from WT and the different IL-12 family cytokine KO mice 
21 d after immunization. (B) DTH response in mice challenged 48 h before 
the end of the experiment. These data are representative of three experi-
ments. (C) Representative histopathology of ocular damage in WT and 
p35 KO mice. Bar, 0.25 mm. (D) LNs were harvested from WT and the dif-
ferent IL-12 family KO mice 21 d after immunization. Cytokine secretion 
was measured in 48-h IRBP-stimulated (30   μ  g/ml) culture supernatants. 
***, P   <   0.001 versus P35 KO; +, P   <   0.05; ++, P   <   0.01 versus WT. Cyto-
kines were measured in pooled supernatants, so although data represent 
a group average of fi  ve mice, no error bars could be generated.     JEM VOL. 205, April 14, 2008 
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PMA plus ionomycin unmasked substantial numbers of CD4  +   
cells capable of producing IFN-     and IL-17 within the in-
fl  ammatory infi  ltrate (  Fig. 3, A and D  , PMA/Io). It is diffi   cult 
to say which condition more accurately refl  ects the situation 
in vivo, where infi  ltrating T cells can come in contact and be 
stimulated by Ag within ocular microcompartments. Never-
theless, supernatants obtained after mincing uveitic eyes in PBS 
to release the infi  ltrating cells and centrifugation can contain 
detectable levels of infl  ammatory cytokines despite a consid-
erable dilution factor (see   Fig. 7 F  ). 
  Both p35 KO and GKO mice had signifi  cantly increased 
EAU scores (  Fig. 3, B and E  ) and enhanced IL-17 production 
(  Fig. 3, C and F  ) compared with their WT counterparts. Fur-
thermore, in both genotypes eye-infi  ltrating cells isolated from 
uveitic eyes and analyzed for intracellular cytokine expression 
contained a higher proportion of cells able to produce IL-17 
than their respective WT controls. Although it is not possible 
to discern whether these were bona fi  de IRBP-specifi  c MHC 
class II  –  restricted Th17 eff  ectors, in all genotypes the vast 
majority of the intraocular cells capable of producing IL-17 
were CD4  +   (  Fig. 3, B and E  ). 
susceptible strain to EAU is the B10.RIII mouse; therefore, 
we examined whether neutralization of p19 aff  ects EAU de-
velopment in this strain. Groups of B10.RIII mice were im-
munized with a uveitogenic protocol of the major pathogenic 
epitope of IRBP, residues 161  –  180. Immunized mice were 
treated with a neutralizing mAb to p19 or p40 or isotype 
control either starting from the priming phase (prevention) 
or starting from the eff  ector phase (reversal), as described in 
Materials and methods. EAU was prevented by early treat-
ment with either anti-p19 or anti-p40 antibodies. However, 
when treatment was started 7 d after immunization, a time 
point when uveitogenic eff  ector T cells have already been 
primed and can be isolated from the LN and spleen, EAU 
development could not be aborted and the disease scores de-
veloped by treated mice were similar to control (  Fig. 2 A  ).   
This suggests that an inductive requirement for IL-23 occurs 
at an early stage of EAU pathogenesis. 
  We examined the adaptive immune responses of mice 
that received early or late treatment. DTH was assessed, and 
lymphoid organs were collected for analysis 17 d after immu-
nization. The eff  ect of the treatment on DTH responses par-
alleled the eff  ect on EAU scores, showing signifi  cantly lower 
response in mice treated from the priming phase but no re-
duction in mice treated starting 7 d after immunization (  Fig. 2, 
A and B  ). In contrast, proliferation (  Fig. 2 C  ) and cytokine 
responses (  Fig. 2 D  ) tended to be reduced in draining LNs 
collected from mice treated with either regimen. This apparent 
discrepancy between responses in vitro (proliferation and cyto-
kines) and in vivo (EAU and DTH) is likely due to the fact 
that the former refl  ects newly primed cells present at that 
point in time in the LN, whereas the latter refl  ects the sum 
total of primed eff  ectors that have already exited into the sys-
temic circulation. Thus, although late treatment inhibits fur-
ther priming of T cells newly arrived in the LN, suffi   cient 
eff  ector T cells have already completed priming and exited 
the LN to mediate DTH and disease. 
  Th17 cells infi  ltrate the eye during uveitis; intensity 
of the IL-17 response is correlated with susceptibility 
  We next wished to examine whether IL-17  –  producing T cells 
are present in uveitic eyes. Mice were immunized with a 
uveitogenic protocol of IRBP. On day 21, when disease was 
fully developed, eyes were collected for analysis of ocular-
infi  ltrating infl  ammatory cells by intracellular staining for IFN-     
and IL-17 combined with immunophenotyping, or for histo-
pathological scoring of disease, and LN cells were stimulated 
in vitro with IRBP for secreted cytokine analysis by ELISA. 
We also examined eyes and responses of p35 KO and IFN-     
KO mice, both of which characteristically develop more se-
vere infl  ammation and retinal damage compared with their 
respective WT counterparts. 
  Direct ex vivo analysis of eye-infi  ltrating cells isolated 
from uveitic WT B10.RIII or C57BL/6 mice for intracellu-
lar IFN-     and IL-17 (after treatment with brefeldin A) revealed 
few or no cells actively producing these cytokines (  Fig. 3, A 
and D  , Unstimulated).   However, a brief incubation with 
    Figure 2.         Anti  –  IL-23 treatment prevents, but does not reverse, 
EAU.   B10RIII mice were immunized with IRBP peptide (161  –  180) as indi-
cated. Groups of fi  ve mice were treated i.p. with antibodies against p19, 
p40, or with isotype from the priming (starting day   –  1) or from the ef-
fector phase of EAU induction (starting day 7) every other day, as indi-
cated in Materials and methods. (A) EAU score evaluated in eyes by 
histopathology 17 d after immunization. (B) DTH responses of mice 
challenged 48 h earlier. (C) LN proliferation to IRBP peptide 161  –  180. 
(D) Cytokine secretion from LN cells stimulated with IRBP peptide 161  –
  180 for 48 h. The data are from a representative experiment of two, with 
fi  ve mice per group. **, P   <   0.01; ***, P   <   0.001 versus the respective iso-
type control.     802 ROLE OF IL-23 AND IL-17 IN EAU | Luger et al.
EAU pathogenesis in the mouse EAU model induced by im-
munization with IRBP in CFA. 
  Th17 effector cells are able to induce EAU 
without participation of Th1 effector cells 
  Although the data described thus far indicate that Th17 is an 
important eff  ector phenotype in EAU, we wished to examine 
whether this eff  ector phenotype is able to induce EAU in the 
absence of Th1. To examine this question, we immunized 
IFN-     KO mice on the B10.RIII background with IRBP 
epitope 161  –  180 and derived a short-term Th17 line by two 
rounds of stimulation with Ag under Th17-inducing condi-
tions. After the second round of stimulation,     50% of the 
CD4  +   cells produced IL-17 by intracellular cytokine staining 
(  Fig. 5 A  ).   In addition, the cells produced very large amounts 
of IL-6 and considerable amounts of TNF-    , as assayed by 
ELISA (Fig. 5 B). More than two rounds of stimulation re-
sulted in progressive loss of IL-17 production, suggesting that 
the Th17 eff  ector phenotype is not stable, at least under the 
in vitro expansion conditions used here. WT as well as IFN-     
KO recipients infused with 5  –  10 million cells immediately af-
ter the second stimulation reproducibly developed EAU with 
high incidence and a predominantly neutrophilic infi  ltrate 
(  Fig. 5, C and D  ). These data indicate that EAU can be in-
duced by IL-17  –  producing T eff  ector cells that are unable to 
  Effector role of IL-17: IL-17 neutralization prevents 
and reverses EAU 
  IL-17 was suggested to be the major pathogenic cytokine in 
infl  ammatory autoimmune diseases such as EAE and CIA. 
We therefore tested whether neutralizing IL-17 in vivo by 
monoclonal anti  –  IL-17 antibody can aff  ect EAU development. 
Neutralization of IL-17 either during the entire course of dis-
ease (starting day   –  1) or during the eff  ector phase only (starting 
day 7) was highly protective (  Fig. 4 A  ).   Immunological re-
sponses, including Ag-specifi  c DTH, proliferation, and pro-
infl  ammatory cytokine production, were strongly reduced in 
both early and late treatment (  Fig. 4, B  –  D  ). The inhibitory 
eff  ect of anti  –  IL-17 on Ag-specifi  c responses is likely indirect, as 
T cells lack expression of the IL-17 receptor although it is pres-
ent on other leukocytes (  18  ). 
  Importantly, unlike neutralization of IL-23, neutralization 
of IL-17 eff  ectively inhibited disease when administered dur-
ing the eff  ector phase starting from day 7 after immunization, 
when uveitogenic eff  ectors have already been generated. Thus, 
unlike IL-23, IL-17 appears to participate in the eff  ector 
phase of the disease. In the aggregate, the data shown in   Figs. 
3 and 4   identify the Th17 Ag-specifi  c eff  ector as central to 
    Figure 3.         Enhanced EAU in IL-12p35 KO and in IFN-     KO mice is 
associated with increased systemic and local IL-17 responses.   WT 
and GKO mice on B10.RIII background (A  –  C) and WT and P35 KO mice on 
C57BL/6 background (D  –  F) were immunized with IRBP. On day 21 after 
immunization, eyes were collected for intracellular cytokine staining of 
eye-infi  ltrating infl  ammatory cells (A and D) or for histopathology (data 
pooled from two experiments with fi  ve mice per group; B and E). *, P   <   
0.05 versus WT. For FACS analysis, cells isolated from eyes were incubated 
either with PMA plus ionomycin and brefeldin A (PMA/Io) or with 
brefeldin A only (unstimulated). Shown are cells gated on CD4. Cytokine 
secretion from LN cells was measured by ELISA after 48 h of culture 
with IRBP.   
    Figure 4.         Anti  –  IL-17 treatment prevents and reverses EAU.   B10RIII 
mice were immunized with IRBP as indicated. Groups of fi  ve mice were 
treated i.p. with antibodies against IL-17 or with isotype from the time of 
priming (starting day   –  1) or from the effector phase of EAU induction 
(starting day 7) every other day. (A) EAU score evaluated in eyes by histo-
pathology 17 d after immunization. (B) Ag-specifi  c DTH response. (C and 
D) LN cells were explanted into culture, and IRBP-specifi  c proliferation 
and cytokine production were measured by multiplex ELISA or by single-
plex ELISA (IL-22). Data show a representative experiment of two. *, P   <   
0.05; **, P   <   0.01; ***, P   <   0.001 versus the related isotype control.     JEM VOL. 205, April 14, 2008 
ARTICLE
803
tected (  Fig. 6 D  ). This is not to suggest that IFN-     is the 
cytokine directly responsible for pathology, but rather to im-
plicate the downstream mechanisms that it induces. There was 
also no detectable production of IL  –  22, a proinfl  ammatory 
cytokine that was recently associated with the Th17 eff  ector 
phenotype and with autoimmunity (  19  –  21  ). 
produce IFN-    , and that disease induction by these cells is 
not dependent on host-produced IFN-    . 
  The Th17 effector is dispensable in EAU induced with a Th1 
cell line 
  Previous data in the EAE and arthritis models suggested that 
IL-17  –  producing eff  ector T cells have central importance in 
pathogenesis, whereas the Th1-type IFN-      –  producing eff  ectors 
have at best a secondary role. Our data shown above appeared 
to suggest that the same may be true for EAU. We therefore 
asked the reciprocal question, namely, whether EAU can be 
induced in the absence of a Th17 response. 
  Cells from a uvetitogenic CD4  +   Th1 cell line specifi  c to 
IRBP peptide 161  –  180 were activated in vitro with their 
peptide Ag. Cytokine production was assayed by ELISA and 
by intracellular cytokine staining. In parallel, activated cells were 
infused into naive syngeneic mice for assessment of EAU in-
duction. The T cell line induced severe EAU in recipient 
mice (  Fig. 6, A and B  ).   ELISA analysis of culture supernatants 
revealed that Th1 cell line in addition to IFN-     also secretes 
large amounts of TNF-     and nanogram amounts of IL-6 
(  Fig. 6 C  ), but no detectable IL-17. Intracellular staining for 
IFN-     and IL-17 revealed that although the line cells ex-
pressed abundant IFN-    , no intracellular IL-17 could be de-
    Figure 5.         Th17 effector cells induce EAU in the absence of an 
IFN-     response.   Short-term Th17 lines were generated from IFN-     KO 
mice immunized with p161  –  180 under Th17 conditions, as described in 
Materials and methods. (A) Intracellular IL-17 expression after a second 
stimulation with p161  –  180. IFN-     expression is confi  rmed to be negative. 
(B) Supernatant from the stimulated cultures was tested for cytokine 
secretion by ELISA. (C and D) Pathogenicity of Th17 cells. Cells were col-
lected from culture after the second cycle of stimulation, and 5   ×   10  6 /
mouse were infused into WT or GKO recipients (fi  ve mice per group). On 
day 10 after transfer, eyes were collected for histopathology and disease 
was scored. Inset shows the infl  ammatory infi  ltrate, similar in WT and 
IFN –     KO. Bar, 0.25 mm (0.02 mm in inset). A representative experiment 
of two is shown.     
    Figure 6.         Severe EAU induced with a T cell line that is stably po-
larized to the Th1 phenotype.   (A and B) After 48 h of stimulation with 
p161  –  180, the indicated number of cells was infused into naive B10RIII 
mice. Shown are average scores (A) and representative histopathology. 
(B) Inset shows the typical infl  ammatory infi  ltrate. Bar, 0.25 mm (0.02 mm 
in inset). (C) ELISA analysis of cytokines in supernatants of the stim-
ulated cells. (D and E) Intracellular cytokine staining after stimulation 
with Ag for 24 h in neutral conditions (D) or for 5 d under Th17-inducing 
conditions (Ag plus IL-23 or Ag plus IL-23 plus anti  –  IFN-    ; E). (F)   “  Park-
ing  ”   of Th1 cells in allotype-congenic recipient mice. After stimulation 
with p161  –  180 in the presence of irradiated APCs, the T cell line was 
infused into naive Thy1.1 x Thy1.2 heterozygous recipients (2   ×   10  6 /
mouse). Note heterozygous Thy1.1/2  +   recipient cells versus Thy1.2  +   donor 
cells by FACS analysis. Thy1.2 single-positive cells were sorted out after 
90 h, stimulated with IRBP peptide 161  –  180 for 24 h (with PMA-ionomy-
cin and brefeldin A added during the last 4 h), and stained for intracellu-
lar IL-17 and IFN-    . Representative experiment of two with fi  ve mice 
per group.     804 ROLE OF IL-23 AND IL-17 IN EAU | Luger et al.
Ag priming in both genotypes, as indicated by equivalent Ag-
specifi  c proliferation in GKO and WT recipients (  Fig. 8 B  ) 
and equivalent IL-4 and IL-5 responses (not depicted). Nota-
bly, the IL-17 response developed by GKO mice was consid-
erably higher than that of the WT (  Fig. 8 C  ), suggesting that 
in this model an IL-17 response in the absence of an IFN-     
response is insuffi   cient, and that priming of an IFN-      –  pro-
ducing eff  ector is needed to elicit disease. These data are con-
sistent with our previous observations and contrast with the 
enhanced EAU elicited in GKO mice after active immuniza-
tion in CFA (  Fig. 3  ) (  22  ). 
  IL-17 KO mice develop EAU and produce 
proinfl  ammatory cytokines 
  Inhibition of EAU in actively immunized mice after IL-17 
neutralization contrasted with the apparent lack of requirement 
for IL-17 in the adoptively transferred disease. We therefore 
examined whether genetic defi  ciency of IL-17 will prevent 
induction of EAU similarly to IL-23 defi  ciency. IL-17 KO mice 
(  23  ) have a targeted deletion of IL-17A, the same IL-17 family 
member recognized by the anti  –  IL-17 antibody clone 1D10 
used throughout this study. IL-17 KO mice and WT controls 
were immunized with a uveitogenic regimen of IRBP. Inhi-
bition of EAU by genetic IL-17 defi  ciency was only partial 
and did not attain statistical signifi  cance (  Fig. 9 A  ).   Although 
LN cell proliferation was reduced, DTH responses were close 
to normal (  Fig. 9, B and C  ). There did not appear to be an 
obvious diff  erence in the histopathological picture that devel-
oped in IL-17 KO as opposed to WT mice, other than severity 
and number of lesions (  Fig. 9 G  ). 
  To address the possibility that IL-17 production by the 
Th1 cell line could have delayed kinetics, or could require 
factor(s) available only in an in vivo environment, we exam-
ined the ability of this T cell line to produce IL-17 (a) after a 
more prolonged stimulation in vitro under Th17-promoting 
conditions, and (b) several days after adoptive transfer into 
mice. For the fi  rst approach, the T cell line was activated in 
culture with p161  –  180 peptide on APCs for 5 d, with rIL-23 
plus anti  –  IFN-    . In a separate experiment, the activated Th1 
cells were adoptively transferred into Thy1  –  congenic mice 
(heterozygous Thy1.1/1.2 double-positive recipients), and 
after 90 h the spleens were analyzed for intracellular IFN-     
versus IL-17 production by the transferred cells (Thy1.2 single-
positive). The data showed that (a) even prolonged in vitro 
stimulation under IL-17  –  promoting conditions failed to in-
duce IL-17 production in the T cell line (  Fig. 6 E  ), and the 
cytokine profi  le remained identical to   Fig. 6 C   (not depicted); 
and (b) line cells   “  parked  ”   in syngeneic hosts, which exhib-
ited ocular signs of EAU, still demonstrated only IFN-     and 
no IL-17 production (  Fig. 6 F  ). 
  Although the Th1 cell line itself cannot produce IL-17, 
the recipients of these cells are IL-17 competent. Therefore, 
it was necessary to examine whether host IL-17 was required 
for pathogenesis of EAU induced by the Th1 line. Flow cyto-
metric analysis of infi  ltrating cells from uveitic eyes of Th1 
cell line recipients revealed few, if any, cells capable of pro-
ducing IL-17, in sharp contrast to actively immunized mice 
(  Fig. 7 A  ).   More importantly, treatment of the recipient mice 
with the same dose of neutralizing anti  –  IL-17 antibody that 
aborts induction of disease in actively immunized mice had 
no eff  ect on EAU scores of the Th1 cell line recipients. In 
contrast, neutralization of IFN-     or TNF-     reduced or largely 
prevented disease, indicating that these cytokines, rather than 
IL-17, have an eff  ector role in the adoptively transferred EAU 
model (  Fig. 7 B  ). 
  Th17 without Th1 is insuffi  cient to support pathology in an 
EAU model induced with in vitro  –  matured, Ag-pulsed DCs 
  The results above indicated that although IL-17 is clearly 
dominant in EAU induced by immunization with IRBP in 
CFA, it is dispensable when EAU is elicited by IRBP-specifi  c 
Th1 eff  ector cells without use of CFA. Another model of EAU 
that is not dependent on CFA is a recently developed EAU 
model induced in B10.RIII mice by injection of IRBP 
161  –  180  –  pulsed, in vitro  –  matured splenic DCs (  22  ). In mice 
with EAU induced by uveitogenic DCs, the Ag-specifi  c IL-17 
response is lower and the IFN-     response is higher than in 
the traditional EAU model induced by immunization in CFA 
(  22  ). To examine the need for an IFN-      –  producing eff  ector, 
we compared the ability of uveitogenic DCs from WT mice 
to induce disease in WT versus IFN-      –  defi  cient recipients. 
DCs isolated from WT mice by immunomagnetic sorting 
were pulsed with IRBP p161  –  180 in presence of LPS and 
anti-CD40 agonistic antibodies and were injected into synge-
neic WT or GKO recipients. Only the WT recipients devel-
oped ocular infl  ammation (  Fig. 8 A  ).   This was despite effi   cient 
    Figure 7.         Host IL-17 does not seem to play a role in pathogenesis 
of EAU induced with the Th1 cell line.   Two million freshly activated 
Th1 line cells were infused i.v. into naive B10.RIII Thy1.1 homozygous 
mice. EAU scores were assessed by fundoscopy. (A) Eyes of recipient mice 
were removed for isolation of infi  ltrating cells 10 d after cell transfer. 
Cells isolated from eyes and incubated with PMA plus ionomycin and 
brefeldin A (PMA/Io) or with brefeldin A only (unstimulated) were stained 
for intracellular IFN-     versus IL-17 and were analyzed by FACS. (B) Recipi-
ent mice were treated with neutralizing antibodies to IL-17, IFN-   ,  or 
TNF-    , or with isotype control (0.25 mg/mouse/day, starting day 0). 10 d 
after transfer, EAU was scored by fundoscopy and confi  rmed by histopa-
thology. Data show histopathology scores of a representative experiment 
of three. +, P   <   0.05; ++, P   <   0.01 versus isotype control; **, P   <   0.01 and 
***,  P   <   0.001  versus  anti – IL-17.   JEM VOL. 205, April 14, 2008 
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sponse systemically and locally correlates with disease severity 
in mice immunized with IRBP/CFA. However, the role of the 
Th17 eff  ector is redundant with Th1, and each eff  ector phe-
notype by itself is suffi   cient to induce pathology in the ab-
sence of the reciprocal hallmark cytokine. In contrast, the role 
of IL-23 in disease pathogenesis is essential and nonredundant, 
raising the possibility that the requirement for IL-23 in EAU 
transcends its role in promoting the Th17 eff  ector response. 
The conditions that drive to a Th17-dominated, or a Th1-
dominated, pathogenic eff  ector response appear to include the 
context in which the fi  rst encounter with auto-Ag occurs. 
  Until recently, the role of IL-12 in promoting the gener-
ation of IFN-      –  producing Th1 eff  ector cells was considered 
the main pathogenic pathway in autoimmune diseases such as 
EAU and EAE (  8, 25, 26  ). However, the import of the IL-23  –
  IL-17 pathway had put in question the need for   “  classical  ”   
Th1 eff  ector cells in development of these autoimmune dis-
eases (  16, 27  ). IL-23 was found to have a signifi  cant role in 
the induction of EAE (  15  ) and CIA (  16  ). In contrast, IL-12 
was found not to be required for EAE and CIA (  28  ). The 
role of IL-23 in autoimmunity was then proposed to be due 
to its ability to promote diff  erentiation of T cells to a distinct 
eff  ector subtype producing mainly IL-17 but not IFN-     (  15, 
17, 29  ). Although more recent data uncovered that the initial 
signal for commitment to the Th17 lineage is mediated by 
TGF-     and IL-6, IL-23 is nevertheless required in vivo for 
expansion and maintenance of the Th17 phenotype (  30, 31  ), 
such that IL-23  –  defi  cient mice  —  whether genetically or by 
antibody neutralization  —  mount a much reduced Th17 re-
sponse (  17   and present data). 
  Our data are in partial agreement with fi  ndings in other 
autoimmune diseases by showing a requirement for IL-23 
rather than IL-12 for disease induction by active immuniza-
tion with auto-Ag in CFA, and by supporting an important 
role for the Th17 eff  ector response in pathogenesis of the re-
sultant disease. Of note is the enhanced systemic and local 
Th17 response in IL-12  –   and IFN  –        –  defi  cient mice, which 
typically exhibit more severe disease than their WT counter-
parts. This suggests that the Th17 eff  ector may become more 
prominent in pathogenesis when the IL  –  12  –  IFN-     pathway 
is reduced or eliminated. IFN-     has been reported to inhibit 
commitment to the Th17 phenotype in vitro (  32  ). Our pre-
sent data, as well as the fi  nding that IRBP-immunized mice 
treated with a neutralizing antibody to IFN  –       develop an el-
evated IL  –  17 response (unpublished data), support the notion 
that this might be the case also in vivo. Studies that preceded 
the   “  Th17 era  ”   had already established that under some cir-
cumstances the IL-12  –  IFN-     pathway (paradoxically) has an 
inhibitory, rather than a pathogenic, role in autoimmunity 
and implicated IFN-      –  induced mechanisms such as induc-
tion of nitric oxide and apoptosis of T eff  ector cells in this 
phenomenon (  12, 33  ). IFN-      –  driven activation of IDO in 
DCs, which causes apoptosis of eff  ector T cells due to tryp-
tophan deprivation (  34  ), and the Tim-3  –  galectin-9 pathway, 
which terminates eff  ector T cell responses (  35  ), have also not 
been excluded. The present results suggest that IFN-      –  driven 
  These data show that EAU can occur in the complete ab-
sence of IL-17A and indicate that other systemic and local 
mechanisms compensate for genetic defi  ciency of IL-17A. 
Multiplex ELISA analysis of Ag-stimulated LN cell superna-
tants revealed that proinfl  ammatory cytokine responses, with 
the expected exception of IL-17A, were overall not very 
severely aff  ected (  Fig. 9 D  ). Flow cytometric analysis of eye-
infi  ltrating cells for intracellular cytokines revealed an increased 
proportion of CD4  +   cells capable of producing IFN-     in IL-
17 KO eyes compared with WT (  Fig. 9 E  ). Notably, su-
pernatants of the minced eye tissue and vitreous fluid that 
remained after isolation of the eye-infi  ltrating leukocytes 
shown in Fig. 9 E (see Materials and methods) analyzed by 
ELISA revealed proinfl  ammatory cytokines such as IL-22, 
IFN-    , IL-6, and IL-1     in amounts similar or even higher 
than WT mice (  Fig. 9 F  ). IL-17F, another IL-17 family 
member believed to be proinfl  ammatory, was not detected 
either in the WT or in the IL-17A KO, suggesting that it was 
not involved in compensatory mechanisms induced by lack 
of IL-17A. Positive controls of supernatant samples   “  spiked  ”   
with recombinant IL-17F confi  rmed that there was no inter-
ference with detection of this cytokine under the assay con-
ditions used (not depicted). IL-17E was not examined, as that 
isoform has already been shown in a previous study to have 
an inhibitory and not a proinfl  ammatory function (  24  ). Thus, 
mechanisms other than IL-17A, including but possibly not 
limited to the Th1 eff  ector response, are suffi   cient to cause 
EAU pathology. 
    DISCUSSION   
  In this study we demonstrate that autoimmunity to retina can 
be either Th17 or Th1 driven. The IL-23  –  IL-17 pathway 
plays an important role in EAU, and intensity of IL-17 re-
    Figure 8.         IFN-     KO (GKO) mice fail to develop EAU after infusion 
of uveitogenic DCs despite the presence of a Th17 response.   Flt3L-
elicited splenic DCs obtained from B10.RIII WT mice were matured and 
pulsed with IRBP p161  –  180 in vitro for 4 h and injected into syngeneic 
WT recipients (  n   = 8) or GKO recipients (  n   = 10). EAU (histopathology) and 
immunological responses were evaluated on day 18 after uveitogenic DC 
transfer. Data show a representative experiment of three. ***, P   <   0.001 
versus WT.     806 ROLE OF IL-23 AND IL-17 IN EAU | Luger et al.
typically produced in large amounts by Th17 cells (  19, 20  ). 
Although the nature of these compensatory mechanisms re-
quires further investigation, the enhanced Th1 response in 
LN and in the eyes of IL-17 KO mice raises the possibility 
that IL-17 may have an antagonistic eff  ect on the develop-
ment of Th1 eff  ectors, just as IFN-     inhibits development of 
Th17 eff  ectors. It should also be noted that although in EAE 
CIA genetic defi  ciency of IL-17A was reported to have a 
strong dampening eff  ect (  23, 37, 38  ), it did not completely 
abrogate disease, pointing to pathogenic eff  ects of cytokines 
other than IL-17. Second, severe EAU can be induced by 
  infusion of stably polarized Th1 eff  ector cells that appear 
to cause pathology without an apparent involvement of host 
IL-17, acting at least in part through TNF-     and IFN-    . Finally, 
inhibition of Th17 eff  ector generation might be an additional 
mechanism that contributes to the increased EAU scores ob-
served in these situations. 
  However, in apparent contrast to studies in EAE and ar-
thritis, our data in EAU suggest that, under some conditions, 
Ag-specifi  c Th17 cells may be dispensable. First, EAU can 
develop in the complete absence of IL  –  17A, as indicated by 
substantial ocular pathology in IL-17A KO mice. Susceptibility 
of IL-17 KO mice contrasts with the protective eff  ect of IL-17 
neutralization in WT mice, a phenomenon not uncommon 
in gene-defi  cient mice and known as phenotypic compensa-
tion (  36  ). It is apparent that congenital lack of IL-17 allows 
emergence of compensatory mechanisms involving Th1 and 
other proinfl  ammatory cytokines including IL-22, which is 
    Figure 9.         IL-17 KO mice develop EAU and maintain production of proinfl  ammatory cytokines.   IL  –  17 KO mice were immunized with a uveito-
genic regimen of IRBP. (A and B) On day 21 after immunization, eyes were collected for EAU evaluation by histopathology (A) and specifi  c DTH responses 
were recorded as the difference between IRBP- and PBS-injected ears (B). (C and D) LN cells were explanted into culture, and IRBP-specifi  c proliferation 
(C) and cytokine production (D) were evaluated. The data show averaged responses from 17 animals in three experiments. (E) On day 21 after immuniza-
tion, eyes were collected and eye-infi  ltrating cells were extracted and stained for intracellular IFN  –       and IL-17. (F) Ocular extracts prepared as described 
in Materials and methods were assayed for cytokine levels. (G) Histopathology of EAU in IL-17 KO and WT mice. Bar, 0.25 mm. Data show a representative 
experiment of three. **, P   <   0.01; ***, P   <   0.001 versus WT.     JEM VOL. 205, April 14, 2008 
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aff  ecting eff  ector mechanisms. Neutralization of IL-17 seems 
to accomplish just that, as it was able to protect even when 
started 7 d after disease induction, a point at which patho-
genic eff  ectors have already been primed. Although IL-23 
could only prevent but not reverse disease, neutralization of 
IL-23 still holds clinical promise. Chronic autoimmunity in-
volves ongoing priming and recruitment of new T cells into 
the eff  ector pool. This continuous priming and recruitment 
cycle is also believed to underlie the phenomenon of epitope 
and Ag spreading, which drives the relapsing nature of dis-
eases such as EAE (  45  ). In keeping with this, neutralization of 
IL-23 prevents relapses in the EAE model (  46  ), supporting 
the rationale of IL-23 targeting in chronic relapsing-remitting 
autoimmune diseases. Although EAU in the B10.RIII mouse 
is monophasic in nature, the phenomenon of epitope spreading 
has been reported in chronic autoimmune uveitis in horses, 
equine recurrent uveitis (  47  ). Importantly, human chronic 
uveitides such as ocular sarcoidosis, Vogt-Koyanagi-Harada 
disease, and sympathetic ophthalmia can present with multiple 
recurrent attacks. If indeed continuous recruitment of new 
eff  ectors underlies these uveitic diseases, anti  –  IL-23, possibly 
as a combination therapy with anti  –  IL-17 to target already 
primed eff  ectors, might be a viable therapeutic approach for 
such types of uveitis. 
  MATERIALS AND METHODS 
  Animals.     IL-23 KO (p19 KO) was described previously (  15  ). IL-17 KO 
mice were produced as described previously (  23  ). IL-12p35 KO (P35 KO), 
IL-12p40 KO (p40 KO), IFN-     KO (GKO; all on C57BL/6 background), 
C57BL/6, and B10RIII mice were purchased from The Jackson Laboratory. 
Animals were kept in a specifi  c pathogen-free facility and given water and 
standard laboratory chow ad libitum. Animal care and use were in compli-
ance with institutional guidelines and with the Association for Research in 
Vision and Ophthalmology Statement for the Use of Animals in Ophthalmi-
cal and Vision Research. The animal study protocol was approved by the 
Animal Care and Use Committee of the NIH. 
uveitogenic DCs are unable to induce EAU in GKO mice 
despite the presence of a strong Th17 response, suggesting that 
an IFN-      –  producing eff  ector is needed to induce pathology. 
  This raises the question of whether the Th17 eff  ector re-
sponse might be dominant particularly in situations where 
induction of disease occurs in the context of strong Toll-like 
receptor (TLR) signals, whereas in other conditions a Th1 re-
sponse may predominate. It is notable that models in which 
IL-17 was reported to be highly dominant, EAE and CIA 
(  15, 16  ) are both induced by immunization with Ag in CFA, 
as is the classical model of EAU. A necessary role for Th17 
in experimental colitis, which is induced in the absence of 
CFA but occurs in the context of strong innate signaling de-
livered by gut bacteria, is in line with this notion (  39, 40  ). 
Thus, factors that may in large measure drive the domi-
nant eff  ector phenotype could include quality/quantity of 
TLR and other innate signals, as well as the identity and diver-
sity of cells functioning as APCs at the site of initial Ag expo-
sure. A synthesis of our data are presented in schematic form 
in   Fig. 10  .   
  The antibody-neutralization data, showing that IL-23 is 
required early whereas IL-17 acts later in the disease process, 
are compatible with the established paradigm that IL-23 acts 
upstream of IL-17 to promote the Th17 eff  ector response. 
However, the evidence that the Th17 eff  ector response may 
in some situations be dispensable suggests that the early re-
quirement for IL-23 may refl  ect function(s) other than sup-
porting the IL-17 eff  ector response. We hypothesize that an 
early nonredundant requirement for IL-23 could involve ef-
fects on APCs, possibly in their maturation and/or early stages 
of eff  ector T cell priming, preceding the commitment to 
Th17 or Th1 phenotype. This notion is supported by recent 
fi  ndings showing dependence on IL-23 of a completely non  –
  T cell  –  driven infl  ammation, infl  ammatory bowel disease in-
duced in RAG        /         mice with agonistic anti-CD40 mAbs (  41  ). 
Additionally, a not very well studied function of IL-23 is its 
role in promoting IFN-      –  producing Th1 cells. Our current 
data suggest that IL-23 also aff  ects the Th1 response, as its 
genetic lack or neutralization by antibodies reduced not only 
the IL-17, but also the IFN-     response to Ag, whereas IL-17 
gene  –  deleted mice had high levels of IFN-    . This is in line 
with data published by others. IL-23 enhanced the secretion 
of IFN-     by human memory T cells (  1, 42  ). Similarly, in 
  Helicobacter hepaticus    –  induced T cell  –  dependent colitis, IL-23 
was needed to drive both IFN-     and IL-17 responses that 
synergized for maximal intestinal infl  ammation (  43  ). Finally, 
administration of an IL-23 plasmid to IL-12p40  –  defi  cient 
mice up-regulated production of IFN-     in response to   Myco-
bacterium tuberculosis   in mice (  44  ). Therefore, IL-23 could be 
required to promote Th1 as well as Th17 eff  ector responses. 
Studies are underway to dissect the disease checkpoints con-
trolled by IL-23 in this model. 
  Both IL-17 and IL-23 emerge as potential new targets for 
therapeutic intervention in the uveitic diseases where this path-
way might play a role in pathogenesis. The   “  holy grail  ”   of 
immunotherapy is to inhibit an ongoing disease process by 
    Figure 10.         Schematic representation of the patterns of effector T 
cell dominance in the different EAU models.   Conditions of initial ex-
posure to Ag that may determine effector dominance are the quality/
quantity of TLR signals and the type/variety of cells participating as APCs.     808 ROLE OF IL-23 AND IL-17 IN EAU | Luger et al.
both the priming and eff  ector phase (prevention protocol) or starting day 7 
through day 15, covering the eff  ector phase only (treatment). In EAU in-
duced by adoptive transfer of the Th1 cell line, treatment with neutralizing 
antibodies was given from day   –  1 through day 10 after transfer. Eyes and 
lymphoid organs were harvested on day 17 after active immunization or on 
days 10  –  14 after adoptive transfer (6 or more days after EAU onset). 
  Isolation of eye-infi  ltrating cells.     Uveitic eyes were collected from fi  ve 
mice per group. External tissues were trimmed, and the eyes were carefully 
dissected along the limbus for lens removal. The remaining tissue was trans-
ferred into 1 ml RPMI, minced with scissors, dispersed by vigorous pipet-
ting, and centrifuged. The clarifi  ed supernatant was collected for cytokine 
analysis, and the cell pellet was resuspended in 3 ml RPMI, 10% FCS, and 
1 mg/ml collagenase D and incubated for 1 h in 37  °  C. Samples were then 
dispersed by pipetting several times, washed, fi  ltered, and suspended in 3 ml 
RPMI plus 10% FCS for counting. Cells were then delivered into a 24-well 
plate (4   ×   10  6   cells/well), incubated with or without PMA, ionomycin, 
and brefeldin A and stained for intracellular cytokine analysis and immuno-
phenotyping by FACS, as described below. Non-infl  amed eyes from un-
immunized donors did not yield suffi   cient leukocytes for analysis. 
  Intracellular cytokine staining and FACS analysis.     In all cases where 
cells were incubated for FACS staining, PMA plus ionomycin (50 and 500 
ng/ml, respectively) were added at the last 4 h of incubation, and 10   μ  g/ml 
brefeldin A was added at the last 2 h. 
  For detection of intracellular expression of IL-17 and IFN-     by FACS 
analysis, Th1 line cells were stimulated with Ag for 24 h under standard con-
ditions, or for 5 d under IL-23  –  polarizing conditions (in the presence of 
10 ng/ml recombinant mouse IL-23, or IL-23 plus 10   μ  g anti  –  mouse IFN-    ). 
Th17 line cells were stimulated with Ag under Th17 conditions (as indi-
cated) for 48 h. T cells were then separated on Ficoll, washed, and stained for 
extracellular CD4, followed by intracellular staining for IFN-     and IL  –  17. 
  Freshly isolated eye-infi  ltrating cells were immediately incubated ex vivo 
with or without PMA plus ionomycin for 4 h. Thereafter, cells were stained for 
extracellular markers, followed by staining for intracellular IFN-     versus IL-17. 
  For ex vivo detection of intracellular IL-17 versus IFN-     after parking 
allotype-marked T cells, Th1 line cells were adoptively transferred i.v. into 
naive Thy1.1   ×   Thy1.2 heterozygous recipients. 4 d later, splenocytes were 
stimulated with IRBP peptide 161  –  180 for 24 h with the addition of PMA 
plus ionomycin, after which cells were stained and analyzed for intracellular 
IL-17 and IFN-     as above. The line cells (WT origin) were identifi  ed by 
gating on Thy1.2 single-positive cells. 
  Culture and characterization of T cell lines.     The uveitogenic Th1 cell 
line specifi  c to a peptide of human IRBP (p16  –  180) has been described (  53  ). 
In brief, the line was derived from draining LNs of B10.RIII mice immu-
nized with human IRBP peptide 161  –  180 and polarized in vitro toward the 
Th1 phenotype by culture in the presence of Ag, IL-12, and anti  –  IL-4. The 
line cells are routinely maintained by alternating cycles of expansion in IL-2 
and restimulation with 1   μ  g/ml p161  –  180 every 2 to 3 wk in the presence 
of syngeneic splenocytes, irradiated with 3,000 rads, as APCs. 
  To generate Th17 cell lines, IFN-     KO mice were immunized with 
20   μ  g IRBP peptide 161  –  180 in CFA. At day 7 after immunization, splenocytes 
and LN cells were combined and CD4 cells were enriched with AutoMacs 
by negative selection (Miltenyi Biotec) and stimulated for 48 h with p161  –
  180 on irradiated splenocytes under Th17-inducing conditions: 20 ng/ml 
rIL-23 (R  &  D Systems), 3 ng/ml TGF-     (PeproTech), 20 ng/ml IL-6 
(PeproTech), and 1   μ  g/ml anti  –  IL-4 (clone 11B11; BD Biosciences). Cells 
were then rested for 1 wk and restimulated as above. At that point, cytokine 
production was evaluated by ELISA or by intracellular cytokine staining, as 
described above, or the collected cells were adoptively transferred into naive 
recipients. Eyes were collected histopathology for 10 d after transfer. 
  Statistical analysis.     Experiments were repeated at least twice, and usually 
three or more times. Experimental groups are typically composed of fi  ve mice. 
  Reagents, Ags, and antibodies.     CFA was purchased from Sigma-Aldrich. 
  M. tuberculosis   strain H37RA was purchased from Thomas Scientifi  c. Puri-
fi  ed   Bordetella pertussis   toxin was purchased from Sigma-Aldrich. IRBP was 
isolated from bovine retinas, as described previously (  48  ). Human IRBP-
  derived peptide 161  –  180 (SGIPYIISYLHPGNTILHVD) was synthesized 
by Fmoc chemistry (model 432A peptide synthesizer; Applied Biosystems). 
Neutralizing antibodies to mouse IL-23 (clone MB379.490.130) (  17  ) and to 
mouse IL-17A (clone 1D10) (  46  ) were produced at DNAX. The C17.8 
(anti  –  IL-12p40, rat IgG2a) hybridoma was provided by G. Trinchieri (Wi-
star Institute, Philadelphia, PA), and neutralizing mAb for IL-12p40, IFN-    , 
and TNF-     was produced by Harlan Bioproducts for Science. FITC-labeled 
anti  –  mouse CD4 (clone L3T4), PE-labeled anti  –  mouse IL-17 (clone TC11-
18H10), APC-labeled anti  –  IFN-     (clone XMG1.2), and cytokine secretion 
blocker (GolgiStop [brefeldin A]) were purchased from Becton Dickinson. 
PMA and ionomycin were purchased from LC Laboratories. 
  EAU induction and scoring.     Induction of EAU by active immunization 
was described previously (  49  ). In brief, immunization included 150   μ  g IRBP 
for C57BL/6 mice and 7   μ  g IRBP peptide 161  –  180 for B10RIII mice. For 
C57BL/6 mice,   B. pertussis   toxin (0.5   μ  g/mouse) was injected i.p. Alterna-
tively, EAU was induced by adoptive transfer of 1  –  2 million freshly stimu-
lated cells from a uveitogenic T cell line. Cells stimulated with Ag for 48 h 
were suspended in medium plus 2% mouse serum and were injected i.p. into 
naive syngeneic recipients. 
  A third method of EAU induction consisted of two subcutaneous injec-
tions 4 d apart of 1  –  2 million IRBP peptide-pulsed, in vitro  –  matured (LPS 
plus anti-CD40) splenic DCs and injection of pertussis on day 2. The method 
has been described previously (  22  ). Clinical EAU was evaluated by fundus 
examination on a scale of 0  –  4 based on the extent of infl  ammation, as de-
scribed in detail elsewhere (  5, 50  ). Eyes harvested 17  –  21 d after immuniza-
tion, or 14 d after adoptive transfer, were processed for histopathology and 
stained with standard hematoxylin and eosin, and the severity of EAU was 
evaluated in a masked fashion on a scale of 0  –  4 using previously published 
criteria based on the number, type, and size of lesions (  5, 50  ). 
  Determination of immunological responses.     DTH to IRBP was evalu-
ated by the ear swelling (  9  ). For Ag-specifi  c lymphocyte proliferation and 
cytokine production in primary cultures, spleens and draining LNs were 
pooled within the group (fi  ve mice per group) and cultured as described 
previously (  51  ) for evaluation of cytokine responses by ELISA and prolifera-
tion by [  3  H]thymidine uptake. Cytokines in 48-h supernatants of Ag-stimu-
lated cells were quantitated using the Pierce Multiplex SearchLight Arrays 
technology (Thermo Fisher Scientifi  c) (  52  ), except for IL-22 and IL-17F. 
IL-22 was measured using an ELISA kit from Antigenix America Inc., per 
the manufacturer  ’  s instructions. IL-17F was determined by an electrochemi-
luminescence sandwich immunoassay performed in Meso-Scale Discovery 
(MSD) in 96-well streptavidin-coated plates. Wells were blocked overnight 
at 4  °  C with 5% BSA in PBS, washed with a Tween20-containing buff  er, 
and reacted with biotinylated monoclonal anti  –  mouse IL-17F (clone 8G6) as 
capture antibody. Test samples were added in duplicate (2 h at room tem-
perature with shaking), washed, and reacted with anti  –  mouse IL-17F pAb 
(AF2057; R  &  D Systems), modifi  ed by MSD Sulfo-TAG NHS Ester as de-
tection antibody. Recombinant mouse IL-17F was used to generate the 
standard curve. The electrochemiluminescence signal was measured in the 
MSD Discovery SECTOR Imager 6000. Cytokines were assayed in pooled 
supernatants, yielding a grouped average of fi  ve, but no error bars. Due to 
inter-experiment variation in absolute values, repeat experiments could not 
be combined. Patterns of response were highly reproducible. Figures depict 
representative experiments. 
  In vivo IL-23, IL-12p40, IL-17, IFN-    , and TNF-     neutralization.   
  B10RIII mice were immunized with IRBP or IRBP uveitogenic peptide 
(161  –  180) as indicated. Mice were injected i.p. with 0.5 mg per dose of anti-
p19, anti-p40, anti  –  IL-17, or isotype controls. Treatment was given every 
other day starting on day     1 through day 15 after immunization, covering JEM VOL. 205, April 14, 2008 
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